- Home
- EMF vs CRBP Comparison
EMF vs CRBP Comparison
Compare EMF & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMF
- CRBP
- Stock Information
- Founded
- EMF 1987
- CRBP 2009
- Country
- EMF United States
- CRBP United States
- Employees
- EMF N/A
- CRBP N/A
- Industry
- EMF Finance/Investors Services
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- EMF Finance
- CRBP Health Care
- Exchange
- EMF Nasdaq
- CRBP Nasdaq
- Market Cap
- EMF 192.8M
- CRBP 158.3M
- IPO Year
- EMF N/A
- CRBP N/A
- Fundamental
- Price
- EMF $11.95
- CRBP $13.00
- Analyst Decision
- EMF
- CRBP Strong Buy
- Analyst Count
- EMF 0
- CRBP 8
- Target Price
- EMF N/A
- CRBP $62.00
- AVG Volume (30 Days)
- EMF 29.3K
- CRBP 313.3K
- Earning Date
- EMF 01-01-0001
- CRBP 11-07-2024
- Dividend Yield
- EMF 6.16%
- CRBP N/A
- EPS Growth
- EMF N/A
- CRBP N/A
- EPS
- EMF N/A
- CRBP N/A
- Revenue
- EMF N/A
- CRBP N/A
- Revenue This Year
- EMF N/A
- CRBP N/A
- Revenue Next Year
- EMF N/A
- CRBP N/A
- P/E Ratio
- EMF N/A
- CRBP N/A
- Revenue Growth
- EMF N/A
- CRBP N/A
- 52 Week Low
- EMF $10.58
- CRBP $5.25
- 52 Week High
- EMF $12.67
- CRBP $61.90
- Technical
- Relative Strength Index (RSI)
- EMF 33.30
- CRBP 25.10
- Support Level
- EMF $11.61
- CRBP $12.90
- Resistance Level
- EMF $13.14
- CRBP $16.21
- Average True Range (ATR)
- EMF 0.29
- CRBP 0.95
- MACD
- EMF -0.06
- CRBP -0.16
- Stochastic Oscillator
- EMF 27.66
- CRBP 1.69
About EMF Templeton Emerging Markets Fund
Templeton Emerging Markets Fund is a closed-end management investment company. It seeks long-term capital appreciation by investing, under normal market conditions, at least 80% of its net assets in emerging country equity securities. It invests in various sectors such as Pharmaceuticals, Beverages, Broadline Retail, Metals &Mining, Banks, Food Products, Semiconductors & Semiconductor Equipment, insurance, Entertainment, and others.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.